LIDR heads into the aftermath of a Q1 miss with short sellers running at their most aggressive level in months — and fresh analyst initiations suggesting the Street still sees a recovery case.
Short interest has more than doubled in the past month. It now covers 9.6% of the free float, up 140% over the past 30 days, and rose a further 16% this week alone to roughly 4.3 million shares. That move is sharp enough to be the primary story. The escalation began in late April, when short positions jumped from around 2.1 million shares to over 4 million in the space of a fortnight — a build that tracked the stock's 36% one-month rally into today's earnings print.
The borrow market tells a nuanced tale. Availability has tightened noticeably — the lending pool is now 68% drawn down, up from below 35% through most of April. That's meaningfully tighter, though still well short of last year's peak of roughly 90% utilisation. Borrowing costs have also climbed, running near 2.85% annually after a brief spike above 4% in late April. The combination of rising short interest and tighter availability suggests the demand for new borrows is real, but supply has not yet become a constraint. There is no squeeze dynamic in place yet.
The catalyst is now on the table. AEye reported Q1 results after the close today, missing on both lines: adjusted EPS came in at -$0.15 versus the -$0.14 consensus, and revenue of $101k fell well short of the $187.5k estimate. The press release headline flagged a "commercial pipeline at record levels" — the kind of language designed to hold the bull case in place even when the numbers disappoint. The ORTEX short score, which integrates borrowing dynamics and positioning signals, has climbed steadily from 60.0 to 62.7 over the past two weeks, confirming the directional pressure from short sellers heading into this print.
Two fresh analyst initiations add texture to the bullish counter-case. Craig-Hallum launched coverage with a Buy and a $3.50 target on April 24. Amerx followed on May 11 with a Buy and a $3.67 target. Both sit meaningfully above the current $2.15 close. The consensus, built on just two Buy ratings, carries a mean target of $4.75 — but that figure is influenced by an older Alliance Global Partners initiation from September 2025 with a $6.00 target, which looks stretched given where the stock is trading today. The two recent initiations are the more relevant signal: specialist coverage being added at this price level points to growing institutional interest, even as earnings momentum remains weak.
Institutional ownership also shifted sharply ahead of this week. Vanguard added over 2 million shares to reach a 6% stake as of March 31. State Street added 1.4 million shares, reported as of April 30. Those are large moves for a stock with no market cap data available and trading in the low single digits — index-driven or ETF rebalancing flows, most likely, but notable for a name this small. On the insider side, the CEO, CFO and company secretary all sold small tranches in February at $1.65, well below current levels. The transaction values were modest, and the significance scores are low. The founder sold in December at $2.40 — now below the current price.
Earlier earnings reactions provide context. The May 8 report produced a 12.7% next-day gain. The March print generated a 15.1% one-day move and a 36.5% five-day run. Both were to the upside. Tonight's miss on revenue — at roughly half the consensus estimate — is a harder read than either of those prior prints. Whether the record-pipeline narrative is enough to sustain the momentum that has carried the stock 36% higher in a month is the question worth tracking when Thursday's session opens.
See the live data behind this article on ORTEX.
Open LIDR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
